The present inventors successfully produced monoclonal antibodies that are specific to only soluble A² oligomers, but do not recognize soluble A² monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimers disease.